Andrew Metry

All publications

Journal articles

• Tuson R, Metry A & Harding K (2024) Cost‐effectiveness analysis of the geko™ device (an NMES technology) in managing venous leg ulcers in UK healthcare settings. International Wound Journal, 21(10).
• Shehata Z, Metry A, Rabea H, El Sherif R, Abdelrahim M & Dawoud D (2023) Early Cost-Utility Analysis of Ataluren and Eteplirsen in the Treatment of Duchenne Muscular Dystrophy in Egypt. Value in Health Regional Issues, 38, 109-117.
• Metry A, Pandor A, Ren S, Shippam A, Clowes M, Dark P, McMullan R & Stevenson M (2023) Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis. Health Technology Assessment, 27(14). View this article in WRRO
• Brook E, McNamara S, Hardern C & Metry A (2022) EE454 A Distributional Cost-Effectiveness Analysis of Screening Strategies for Ovarian Cancer. Value in Health, 25(12), S144-S145.
• Duarte A, Walker S, Metry A, Wong R, Panovska-Griffiths J & Sculpher M (2021) Jointly modelling economics and epidemiology to support public policy decisions for the COVID-19 response : a review of UK studies. PharmacoEconomics, 39(8), 879-887.
• Pennington R, Alshreef A, Flight L, Metry A, Poku E, Hykin P, Sivaprasad S, Prevost AT, Vasconcelos JC, Murphy C , Kelly J et al (2021) Cost effectiveness of ranibizumab vs aflibercept vs bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the LEAVO study. PharmacoEconomics. View this article in WRRO
• Stevenson M, Metry A & Messenger M (2021) Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E : rapid cost-effectiveness analysis. Health Technology Assessment, 25(21), 1-68.
• Pennington B, Alshreef A, Flight L, Metry A, Poku E, Hykin P, Sivaprasad S, Prevost AT, Vasconcelos JC, Murphy C , Kelly J et al () Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. PharmacoEconomics.
• Stevenson M, Metry A & Messenger M () Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis. Health Technology Assessment, 25(39), 1-74.
• Hykin P, Prevost AT, Sivaprasad S, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Alshreef A, Flight L, Pennington R , Hounsome B et al () Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health Technology Assessment.
• Rafia R, Metry A & Wailoo A () A cost-effectiveness analysis of remdesivir for the treatment of hospitalised patients with COVID-19 in England and Wales. Value in Health.

Conference proceedings papers

• Metry A, Sullivan W, Kearns BC & Bullement A (2019) PDB32 WOULD A COHORT-LEVEL APPROACH TO COST-EFFECTIVENESS MODELLING HAVE LED TO A DIFFERENT DECISION IN AN IMPORTANT NICE APPRAISAL FOR OBESITY PATIENTS?. Value in Health, Vol. 22 (pp S577-S578)
• Metry AB, Elsisi GH & Elshafei ZA (2017) COST-MINIMIZATION ANALYSES OF BIOLOGICAL THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS FROM THE EGYPTIAN HEALTHCARE SYSTEM PERSPECTIVE. VALUE IN HEALTH, Vol. 20(9) (pp A535-A536)
• Elmansy H, Metry AB, Eldessouki R & Elsisi G (2015) Cost-Effectiveness of Zoledronic Acid Versus Alendronic Acid In The Treatment of Osteoporosis In Postmenopausal Egyptian Patients: Decision Analysis. Value in Health, Vol. 18(7) (pp A646-A646)
• Elshikh EA, Anan I, Ebaid AA, Gamal DA A, Hamed MM, Mouein EA & Metry AB (2015) A Cross-Sectional Epidemiological Cancer Registry In Egypt. Value in Health, Vol. 18(7) (pp A437-A437)
• Taleb AAM, Saad AS, Kamal KA & Metry AB (2015) DEVELOPING HOSPITAL BASED HTA FOR EGYPTIAN CANCER PATIENTS. VALUE IN HEALTH, Vol. 18(3) (pp A102-A102)

Preprints

• Tuson R, Metry A & Harding K (2024) Cost-effectiveness analysis of the geko™ device (an NMES technology) in managing venous leg ulcers in UK healthcare setting, Cold Spring Harbor Laboratory.